Researchers have uncovered an increased risk of cervical cancer in women whose cervical cells test positive for certain high-risk human papillomavirus (HPV) types but do not show any signs of cellular abnormalities. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help refine guidelines for cervical cancer screening.
Certain HPV types can cause cervical cancer, with types HPV16 and HPV18 being responsible for most cases. Due to this causative link, sensitive tests for HPV infection have been developed to help identify women who are at high risk of developing cervical cancer. A team of investigators at the Karolinska University Hospital and Institute in Sweden, along with collaborators in the United States, Slovenia, and Belgium, conducted a study to determine what risk women may face if they test positive for HPV but their cervical cells do not show any indication of being cancerous (through a test called liquid-based cytology, which is similar to the Papanicolaou [Pap] smear but according to some reports, more sensitive).
The study included 576 women with normal findings on liquid-based cytology of the cervix who were followed for 9 years. During that follow-up period, 92 of the women developed high-grade pre-cancerous cervical changes and 4 women developed cervical cancer. These 96 women (cases) were compared with 480 women with normal findings on follow-up cervical cytology and matched by age (controls). All 576 baseline cervical samples were tested retroactively for HPV.
The researchers found that a positive HPV finding was much more common among the cases than among the controls. For women younger than 30 years, only HPV16 and HPV18 were present significantly more often among cases than controls and were therefore associated with an increased risk of pre-cancerous cervical changes and cervical cancer. For women aged 30 years and older, other HPV types in addition to HPV16 and HPV18 conferred significant risk.
"These findings can help in the ongoing development of guidelines for cervical cancer screening. They strongly indicate that testing for HPV needs to be incorporated into screening programs," said principal investigator Sonia Andersson, MD, PhD, of the Karolinska University Hospital and Institute in Sweden. "Women younger than 30 with a positive HPV16 or HPV18 finding need to be closely followed, whereas other HPV types are much less likely to be associated with increased risk in these younger women. Among women above age 30, any HPV positive finding should be closely followed." Dr. Andersson also noted that women who are found to have pre-cancerous cervical changes should receive appropriate gynecologic treatment to help prevent the development of invasive cervical cancer. She emphasized that women need to fully participate in cervical cancer screening; to have accurate knowledge about HPV and cervical pre-cancer and cancer; and to be continuously informed about cervical cancer screening guidelines as they evolve.
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. A free abstract of this article will be available via the Cancer News Room upon online publication. For more information or to obtain a PDF of any study, please contact:
"The impact of HPV status on development of high-grade cervical intraepithelial neoplasia in women negative for intraepithelial lesions or malignancy at baseline: 9-year Swedish nested case-control follow-up study." Maria Fröberg, Ellinor Östensson, Karen Belkic?, Anja Oštrbenk, Mario Poljak, Miriam Mints, Marc Arbyn, and Sonia Andersson. CANCER; Published Online: December 10, 2018 (DOI: 10.1002/cncr.31788).
URL Upon Publication: http://doi.
Author Contact: The Karolinska Institute's Press Office, at email@example.com or +46 8 524 860 77.
About the Journal
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online at http://wileyonlinelibrary.
Follow us on Twitter @JournalCancer
Wiley is a global leader in research and education. Our online scientific, technical, medical, and scholarly journals, and our digital learning, assessment, certification and student-lifecycle services and solutions help universities, academic societies, businesses, governments and individuals to achieve their academic and professional goals. For more than 200 years, we have delivered consistent performance to our stakeholders. The Company's website can be accessed at http://www.